A 59-year-old man with a 10-year history of diffuse lymphadenopathy, presented to the Emergency Department with progressively increasing shortness of breath and pleuritic chest pain of 3 days' duration. A diffuse hyperpigmented maculopapular rash associated with urticaria after consuming nonsteroidal anti-inflammatory drugs had been present for 30 years. Over the past decade, the patient experienced multiple syncopal episodes and chronic diarrhea triggered by consumption of animal products. The white blood cell count ranged from 11,000 to 30,300 per lL with granulocytes numbering between 5500 and 22,400 per lL. The absolute eosinophil count ranged from 720 to 1200 per lL. Computerized axial tomography scan of the abdomen in 2006 revealed diffuse lymphadenopathy, hepatosplenomegaly, and osteosclerosis. Inguinal and cervical lymph node biopsies in 2006 and 2012, respectively, only showed reactive lymphadenopathy. In 2009, the patient was diagnosed with nonischemic cardiomyopathy and a left ventricular ejection fraction of 40% by echocardiogram. Two bone marrow biopsies performed in 2012 showed lymphohistiocytic aggregates, but were negative for malignancy; peripheral blood, lymph node, and bone marrow flow cytometry were also unrevealing.
The eosinophil count on admission was 500 per lL, ruling out hypereosinophilic syndrome. Cardiomegaly was seen on Radiography, and echocardiography showed a large pericardial effusion with impaired right ventricular filling (Fig. 1A ) and significant respiratory variation in transmitral valve flow velocities (Fig. 1B) . A pericardial window was placed urgently, with drainage of approximately 1 L of exudative pericardial fluid. During the surgery, the patient suffered sudden cardiovascular collapse, requiring intravenous epinephrine infusion for 24 h. Serum tryptase levels drawn subsequently were 115 and 154 ng/mL (upper limit of 10 ng/mL).
Pericardial tissue showed scattered c-Kit + (Fig. 1C ), CD25 + mast cells (<15 cells) in a background of diffuse mono nuclear inflammatory infiltrate (Fig. 1D) This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
( Fig. 1F) , CD2 -mast cells consistent with Systemic Mastocytosis (SM). Beta-blockade and ACE-Inhibitor therapy was withheld due to concern for lowering of the anaphylactic threshold, and the patient was discharged with oral colchicine, a mast cell stabilizer (Montelukast) and a selective H-1 blocker (Fexofenadine).
Among adults with SM, >90% express an activating D816V mutation of KIT that leads to the proliferation of morphologically and immunophenotypically abnormal mast cells [1] . The WHO major diagnostic criteria for SM is a bone marrow biopsy showing multifocal aggregates with >15 mast cells/hpf. Minor criteria include blood, bone marrow, or extracutaneous organ biopsy showing D816V mutation; mast cells with CD25 and/or CD2 expression; multiple serum tryptase levels >20 ng/mL and >25% of mast cells having abnormal morphology on biopsy. One major and two minor or three minor criteria are sufficient to clinch the diagnosis. Normal myocardium is populated by mast cells with granules containing fibrogenic proinflammatory cytokines such as tumor necrosis factor-a, transforming growth factor (TGF)-b, interleukin-4, platelet-derived growth factor, and fibroblast growth factor, in addition to histamine, tryptase, chymase, and renin. Many patients with mast cell activation disorders tend to develop left ventricular diastolic dysfunction. Mast cell-derived histamine also stimulates fibroblast proliferation and collagen synthesis. Administration of an H2 blocker in a prospective study improved both cardiac symptoms and ventricular remodeling in patients with heart failure [2] . In failing hearts, over 75% of fibrogenic angiotensin II is derived from the angiotensin-converting enzyme (ACE)-independent chymase pathway [3] . Chymase also mediates direct fibrogenic activity through activation of TGF-b-induced Smad-dependent pathways [4] . Chymase inhibition attenuates matrix metalloproteinases in rodent, porcine, and dog models of heart failure [5] . Systolic and diastolic dysfunction from cardiac remodeling due to both pressure and volume overload can be attenuated by mast cell stabilizers in animal models [6] .
We describe the first reported case of SM presenting as cardiac tamponade with pericardial CD25 + mast cells. The episode of hypotension was likely due to distributive shock from pericardial mast cell degranulation. We propose that abnormal, hyperactive mast cells served as mediators of the inflammatory response in myocardial and pericardial tissue, contributing to production of the pericardial effusion eventually leading to tamponade. Further studies are necessary to fully understand the mechanism behind this occurrence.
